Proteome analysis of schizophrenia brain tissue

World Journal of Biological Psychiatry

Volumn 11, Issue 2, 2010, Pages 110-120

  Martins De Souza, Daniel ^a,b   Dias Neto, Emmanuel ^b,d   Schmitt, Andrea ^c   Falkai, Peter ^c   Gormanns, Philipp ^a   MacCarrone, Giuseppina ^a   Turck, Christoph W ^a   Gattaz, Wagner F ^b  

^a MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

^c UNIVERSITY OF GÖTTINGEN   (Germany)

^d Centro de Pesquisas   (Brazil)

Author keywords

Mass spectrometry; Post mortem brains; Proteome; Proteomics; Schizophrenia

Indexed keywords

BIOLOGICAL MARKER;

COGNITION; ENERGY METABOLISM; HUMAN; HUMAN TISSUE; MASS SPECTROMETRY; NERVE CELL PLASTICITY; PATHOPHYSIOLOGY; PROTEIN EXPRESSION; PROTEOMICS; REVIEW; SCHIZOPHRENIA; SOCIAL ASPECT; TWO DIMENSIONAL GEL ELECTROPHORESIS;

BIOLOGICAL MARKERS; BRAIN; BRAIN CHEMISTRY; CYTOSKELETON; ENERGY METABOLISM; HUMANS; NERVE TISSUE PROTEINS; OLIGODENDROGLIA; PROTEOMICS; REPRESSOR PROTEINS; SCHIZOPHRENIA;

EID: 77649145378     PISSN: 15622975     EISSN: 18141412     Source Type: Journal    
DOI: 10.3109/15622970903490626     Document Type: Review

References (95)

1. Altar CA, Jurata LW, Charles V, Lemire A, Liu P, Bukhman Y, et al. 2005. Defi cient hippocampal neuron expression of proteasome, ubiquitin, and mitochondrial genes in multiple schizophrenia cohorts. Biol Psychiatry 58:85-96.
2. Andrieux A, Salin PA, Vernet M, Kujala P, Baratier J, Gory-Fauré S, et al. 2002. The suppression of brain cold-stable micro tubules in mice induces synaptic defects associated with neuroleptic-sensitive behavioral disorders. Genes Dev 16: 2350-2364.
3. Arion D, Unger T, Lewis DA, Levitt P, Mirnics K. 2007. Molecular evidence for increased expression of genes related to immune and chaperone function in the prefrontal cortex in schizophrenia. Biol Psychiatry 62:711-721.
4. Aston C, Jiang L, Sokolov BP. 2004. Microarray analysis of postmortem temporal cortex from patients with schizophrenia. J Neurosci Res 77:858-866.
5. Baranzini SE, Elfstrom C, Chang SY, Butunoi C, Murray R, Higuchi R, Oksenberg JR. 2000. Transcriptional analysis of multiple sclerosis brain lesions reveals a complex pattern of cytokine expression. J Immunol 165:6576-6582.
6. Beasley CL, Pennington K, Behan A, Wait R, Dunn MJ, Cotter D. 2006. Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: Evidence for disease-associated changes. Proteomics 6:3414-3425.
7. Behan A, Byrne C, Dunn MJ, Cagney G, Cotter DR. 2009. Proteomic analysis of membrane microdomain-associated proteins in the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder reveals alterations in LAMP, STXBP1 and BASP1 protein expression. Mol Psychiatry 14:601-613.
8. Benitez-King G, Ramirez-Rodriguez G, Ortiz L, Meza I. 2004. The neuronal cytoskeleton as a potential therapeutical target in neurodegenerative diseases and schizophrenia. Curr Drug Targets CNS Neurol Disord 3:515-533.
9. Ben-Shachar D. 2002. Mitochondrial dysfunction in schizophrenia: a possible linkage to dopamine. J Neurochem 83: 1241-1251.
10. Ben-Shachar D, Laifenfeld D. 2004. Mitochondria, synaptic plasticity, and schizophrenia. Int Rev Neurobiol 59:273-296.
11. Ben-Shachar D, Zuk R, Gazawi H, Reshef A, Sheinkman A, Klein E. 1999. Increased mitochondrial complex I activity in platelets of schizophrenia patients. Int J Neuropsychopharmacol 2:245-253.
12. Bergson C, Levenson R, Goldman-Rakic PS, Lidow MS. 2003. Dopamine receptor-interacting proteins: the Ca2+ connection in dopamine signaling. Trends Pharmacol Sci 24:486-492.
13. Birner R, Nebauer R, Schneiter R, Daum G. 2003. Synthetic lethal interaction of the mitochondrial phosphatidyleth-anolamine biosynthetic machinery with the prohibitin complex of Saccharomyces cerevisiae. Mol Biol Cell 14: 370-383.
14. Bowden NA, Weidenhofer J, Scott RJ, Schall U, Todd J, Michie PT, Tooney PA. 2006. Preliminary investigation of gene expression profi les in peripheral blood lymphocytes in schizophrenia. Schizophr Res 82:175-183.
15. Brockschnieder D, Sabanay H, Riethmacher D, Peles E. 2006. Ermin, a myelinating oligodendrocyte-specifi c protein that regulates cell morphology. J Neurosci 26:757-762.
16. Brun P, Bégou M, Andrieux A, Mouly-Badina L, Clerget M, Schweitzer A, et al. 2005. Dopaminergic transmission in STOP null mice. J Neurochem 94:63-73.
17. Bruneel A, Labas V, Mailloux A, Sharma S, Royer N, Vinh J, et al. 2005. Proteomics of human umbilical vein endothe-lial cells applied to etoposide-induced apoptosis. Proteomics 5:3876-3884.
18. Byne W, Dracheva S, Chin B, Schmeidler JM, Davis KL, Haroutunian V. 2008. Schizophrenia and sex associated differences in the expression of neuronal and oligodendrocyte-specifi c genes in individual thalamic nuclei. Schizophr Res 98:118-128.
19. Chatterjee D, Bai Y, Wang Z, Beach S, Mott S, Roy R, et al. 2004. RKIP sensitizes prostate and breast cancer cells to drug-induced apoptosis. J Biol Chem 279:17515-17523.
20. Clark D, Dedova I, Cordwell S, Matsumoto I. 2006. A proteome analysis of the anterior cingulate cortex gray matter in schizophrenia. Mol Psychiatry 11:459-470.
21. Clinton SM, Haroutunian V, Davis KL, Meador-Woodruff JH. 2003. Altered transcript expression of NMDA receptor-associated postsynaptic proteins in the thalamus of subjects with schizophrenia. Am J Psychiatry 160:1100-1109.
22. Dale LB, Babwah AV, Ferguson SS. 2002. Mechanisms of meta-botropic glutamate receptor desensitization: role in the patterning of effector enzyme activation. Neurochem Int 41: 319-326.
23. Denarier E, Aguezzoul M, Jolly C, Vourc'h C, Roure A, Andrieux A, et al. 1998. Genomic structure and chromosomal mapping of the mouse STOP gene (Mtap6). Biochem Biophys Res Commun 243:791-796.
24. Deng W, Poretz RD. 2003. Oligodendroglia in developmental neurotoxicity. Neurotoxicology 24:161-178.
25. Dracheva S, Davis KL, Chin B, Woo DA, Schmeidler J, Haroutunian V. 2006. Myelin-associated mRNA and protein expression defi cits in the anterior cingulate cortex and hippocampus in elderly schizophrenia patients. Neurobiol Dis 21:531-540.
26. Du Y, Dreyfus CF. 2006. Oligodendrocytes as providers of growth factors. J Neurosci Res 68:647-654.
27. Edwards MM, Robinson SR. 2006. TNF alpha affects the expression of GFAP and S100B: implications for Alzheimer's disease. J Neural Transm 113:1709-1715.
28. Ehlers MD, Tingley WG, Huganir RL. 1995. Regulated subcel-lular distribution of the NR1 subunit of the NMDA receptor. Science 269:1734-1737.
29. English JA, Dicker P, Föcking M, Dunn MJ, Cotter DR. 2009. 2-D DIGE analysis implicates cytoskeletal abnormalities in psychiatric disease. Proteomics 9:3368-3382.
30. Foong J, Maier M, Barker GJ, Brocklehurst S, Miller DH, Ron MA. 2000. In vivo investigation of white matter pathology in schizophrenia with magnetization transfer imaging. J Neurol Neurosurg Psychiatry 68:70-74.
31. Greene ND, Bamidele A, Choy M, de Castro SC, Wait R, Leung KY, et al. 2007. Proteome changes associated with hippocampal MRI abnormalities in the lithium pilocarpine-induced model of convulsive status epilepticus. Proteomics 7:1336-1344.
32. Gygi SP, Corthals GL, Zhang, Y, Rochon Y, Aebersold, R. 2000. Evaluation of two-dimensional gel electrophoresis-based proteome analysis technology. Proc Natl Acad Sci USA 97: 9390-9395.
33. Hakak Y, Walker JR, Li C, Wong WH, Davis KL, Buxbaum JD, et al. 2001. Genome-wide expression analysis reveals dysregu-lation of myelination-related genes in chronic schizophrenia. Proc Natl Acad Sci USA 98:4746-4751.
34. Hamajima N, Matsuda K, Sakata S, Tamaki N, Sasaki M, Nonaka M. 1996. A novel gene family defi ned by human dihydropyrimidi-nase and three related proteins with differential tissue distribution. Gene 180:157-163.
35. Hazlett EA, Buchsbaum MS, Byne W, Wei TC, Spiegel-Cohen J, Geneve C, et al. 1999. Three-dimensional analysis with MRI and PET of the size, shape, and function of the thalamus in the schizophrenia spectrum. Am J Psychiatry 156:1190-1199.
36. Honer WG, Falkai P, Chen C, Arango V, Mann JJ, Dwork AJ. 1999. Synaptic and plasticity-associated proteins in anterior frontal cortex in severe mental illness. Neuroscience 91: 1247-1255.
37. Huang JT, Wang L, Prabakaran S, Wengenroth M, Lockstone HE, Koethe D, et al. 2008. Independent protein-profi ling studies show a decrease in apolipoprotein A1 levels in schizophrenia CSF, brain and peripheral tissues. Mol Psychiatry 13: 1118-1128.
38. Johnston-Wilson NL, Sims CD, Hofmann JP, Anderson L, Shore AD, Torrey EF, Yolken RH. 2000. Disease-specifi c alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropa-thology Consortium. Mol Psychiatry 5:142-149.
39. Kanehisa M, Goto S. 2000. KEGG: kyoto encyclopedia of genes and genomes. Nucleic Acids Res 28:27-30.
40. Katsel P, Davis KL, Haroutunian V. 2005. Variations in myelin and oligodendrocyte-related gene expression across multiple brain regions in schizophrenia: a gene ontology study. Schizophr Res 79:157-173.
41. Khaitovich P, Lockstone HE, Wayland MT, Tsang TM, Jayatilaka SD, Guo AJ, et al. 2008. Metabolic changes in schizophrenia and human brain evolution. Genome Biol 9:R124.
42. Kinoshita A, Yamada K, Kohmura E, Hayakawa T. 1990. Effect of astrocyte-derived factors on ischemic brain edema induced by rat MCA occlusion. APMIS 98(9):851-857.
43. Kubicki M, Park H, Westin CF, Nestor PG, Mulkern RV, Maier SE, et al. 2005. DTI and MTR abnormalities in schizophrenia: Analysis of white matter integrity. Neuroimage 15:1109-1118. (Pubitemid 40806489)
44. Larsen TK, Opjordsmoen S. 1996. Early identifi cation and treatment of schizophrenia: conceptual and ethical considerations. Psychiatry 59:371-380.
45. Lewis DA, Levitt P. 2002. Schizophrenia as a disorder of neu-rodevelopment. Annu Rev Neurosci 25:409-432.
46. Liang P, MacRae TH. 1997. Molecular chaperones and the cytoskeleton. J Cell Sci 110:1431-1440
47. Link AJ, Eng J, Schieltz DM, Carmack E, Mize GJ, Morris DR, et al. 1999. Direct analysis of protein complexes using mass spectrometry. Nat Biotechnol 17:676-680.
48. Manjeshwar S, Branam DE, Lerner MR, Brackett DJ, Jupe ER. 2003. Tumor suppression by the prohibitin gene 3'untranslated region RNA in human breast cancer. Cancer Res 63: 5251-5256.
49. Marenco S, Weinberger DR. 2000. The neurodevelopmental hypothesis of schizophrenia: following a trail of evidence from cradle to grave. Dev Psychopathol 12:501-527.
50. Martins-de-Souza D, Gattaz WF, Schmitt A, Rewerts C, Marangoni S, Novello JC, et al. 2009a. Alterations in oli-godendrocyte proteins, calcium homeostasis and new potential markers in schizophrenia anterior temporal lobe are revealed by shotgun proteome analysis. J Neural Transm 116:275-289.
51. Martins-de-Souza D, Gattaz WF, Schmitt A, Maccarrone G, Hunyadi-Gulyás E, Eberlin MN, et al. 2009b. Proteomic analysis of dorsolateral prefrontal cortex indicates the involvement of cytoskeleton, oligodendrocyte, energy metabolism and new potential markers in schizophrenia. J Psychiatr Res 43: 978-986.
52. Martins-de-Souza D, Gattaz WF, Schmitt A, Rewerts C, Maccarrone G, Dias-Neto E, Turck CW. 2009c. Prefrontal cortex shotgun proteome analysis reveals altered calcium homeostasis and immune system imbalance in schizophrenia. Eur Arch Psychiatry Clin Neurosci 259:151-163.
53. Martins-de-Souza D, Gattaz WF, Schmitt A, Novello JC, Marangoni S, Turck CW, Dias-Neto E. 2009d. Proteome analysis of schizophrenia patients Wernicke's area reveals an energy metabolism dysregulation. BMC Psychiatry 9:17.
54. McCullumsmith RE, Gupta D, Beneyto M, Kreger E, Haroutunian V, Davis KL, Meador-Woodruff JH. 2007. Expression of transcripts for myelination-related genes in the anterior cingulate cortex in schizophrenia. Schizophr Res 90:15-27.
55. Middleton FA, Mirnics K, Pierri JN, Lewis DA, Levitt P. 2002. Gene expression profi ling reveals alterations of specifi c metabolic pathways in schizophrenia. J Neurosci 22:2718-2729.
56. Middleton FA, Peng L, Lewis DA, Levitt P, Mirnics K. 2005. Altered expression of 14-3-3 genes in the prefrontal cortex of subjects with schizophrenia. Neuropsychopharmacology 30: 974-983.
57. Mishra S, Murphy LC, Murphy LJ. 2006. The Prohibitins: emerging roles in diverse functions. J Cell Mol Med 10:353-363.
58. Moore C, Perry AC, Love S, Hall L. 1996. Sequence analysis and immunolocalisation of phosphatidylethanolamine binding protein (PBP) in human brain tissue. Brain Res Mol Brain Res 37:74-78.
59. Müller N, Schwarz MJ. 2008. A psychoneuroimmunological perspective to Emil Kraepelins dichotomy: schizophrenia and major depression as inflammatory CNS disorders. Eur Arch Psychiatry Clin Neurosci 258:97-106.
60. Nicholl ID, Quinlan RA. 1994. Chaperone activity of alpha-crystallins modulates intermediate fi lament assembly. EMBO J 13:945-953.
61. Pennington K, Beasley CL, Dicker P, Fagan A, English J, Pariante CM, et al. 2009. Prominent synaptic and metabolic abnormalities revealed by proteomic analysis of the dorsolateral pre-frontal cortex in schizophrenia and bipolar disorder. Mol Psychiatry 13:1102-1117
62. Pennington K, Dicker P, Dunn MJ, Cotter DR. 2008. Proteomic analysis reveals protein changes within layer 2 of the insular cortex in schizophrenia. Proteomics 8:5097-5107.
63. Perkins DO. 2007. Neuroprotection: a new strategy in the treatment of schizophrenia. Early detection and intervention. CNS Spectr 12:10-13.
64. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, Griffi n JL, et al. 2004. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry 9:684-697, 643. (Pubitemid 38932173)
65. Prabakaran S, Wengenroth M, Lockstone HE, Lilley K, Leweke FM, Bahn S. 2007. 2-D DIGE analysis of liver and red blood cells provides further evidence for oxidative stress in schizophrenia. J Proteome Res 6:141-149.
66. Puricelli L, Iori E, Millioni R, Arrigoni G, James P, Vedovato M, Tessari P. 2006. Proteome analysis of cultured fi broblasts from type 1 diabetic patients and normal subjects. J Clin Endocrinol Metab 91:3507-3514.
67. Rapoport JL, Addington AM, Frangou S, Psych MR. 2005. The neurodevelopmental model of schizophrenia: update 2005. Mol Psychiatry 10:434-449
68. Schoentgen F, Jollès P. 1995. From structure to function: possible biological roles of a new widespread protein family binding hydrophobic ligands and displaying a nucleotide binding site. FEBS Lett 369:22-26.
69. Segal D, Koschnick JR, Slegers LH, Hof PR. 2007. Oligoden-drocyte pathophysiology: a new view of schizophrenia. Int J Neuropsychopharmacol 10:503-511.
70. Seliger B, Dressler SP, Wang E, Kellner R, Recktenwald CV, Lottspeich F, et al. 2009. Combined analysis of transcrip-tome and proteome data as a tool for the identifi cation of candidate biomarkers in renal cell carcinoma. Proteomics 9: 1567-1581.
71. Sikich L, Frazier JA, McClellan J, Findling RL, Vitiello B, Ritz L, et al. 2008. Double-blind comparison of fi rst-and second-generation antipsychotics in early-onset schizophrenia and schizo-affective disorder: fi ndings from the treatment of early-onset schizophrenia spectrum disorders (TEOSS) study. Am J Psychiatry 165:1420-1431
72. Sivagnanasundaram S, Crossett B, Dedova I, Cordwell S, Matsumoto I. 2007. Abnormal pathways in the genu of the corpus callosum in schizophrenia pathogenesis: a proteome study. Proteomics Clin Appl 1:1291-1305.
73. Smalla KH, Mikhaylova M, Sahin J, Bernstein HG, Bogerts B, Schmitt A, et al. 2008. A comparison of the synaptic proteome in human chronic schizophrenia and rat ketamine psychosis suggest that prohibitin is involved in the synaptic pathology of schizophrenia. Mol Psychiatry 13:878-896.
74. Smutzer G, Lee VM, Trojanowski JQ, Arnold SE. 1998. Human olfactory mucosa in schizophrenia. Ann Otol Rhinol Laryngol 107:349-355.
75. Steffek AE, McCullumsmith RE, Haroutunian V, Meador-Woodruff JH. 2008. Cortical expression of glial fi brillary acidic protein and glutamine synthetase is decreased in schizophrenia. Schizophr Res 103:71-82.
76. Strous RD, Greenbaum L, Kanyas K, Merbl Y, Horowitz A, Karni O, et al. 2006. Association of the dopamine receptor interacting protein gene, NEF3, with early response to antip-sychotic medication. Int J Neuropsychopharmacol 31:1-13.
77. Strous RD, Shoenfeld Y. 2006. Schizophrenia, autoimmunity and immune system dysregulation: a comprehensive model updated and revisited. J Autoimmun 27(2):71-80.
78. Sultana R, Boyd-Kimball D, Cai J, Pierce WM, Klein JB, Merchant M, Butterfi eld DA. 2007. Proteomics analysis of the Alzheimer's disease hippocampal proteome. J Alzheimers Dis 11:153-164.
79. Sweitzer SM, Hinshaw JE. 1998. Dynamin undergoes a GTP-dependent conformational change causing vesiculation. Cell 93(6):1021-1029.
80. Tamminga CA, Thaker GK, Buchanan R, Kirkpatrick B, Alphs LD, Chase TN, Carpenter WT. 1992. Limbic system abnormalities identifi ed in schizophrenia using positron emission tomography with fluorodeoxyglucose and neocortical alterations with defi cit syndrome. Arch Gen Psychiatry 49: 522-530.
81. Teunissen CE, Dijkstra C, Polman C. 2005. Biological markers in CSF and blood for axonal degeneration in multiple sclerosis. Lancet Neurol 4:32-41.
82. Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB, et al. 2003. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet 362:798-805.
83. van Os J, Rutten BPF, Poulton R. 2010. Gene-environment interactions for searchers: Collaboration between epidemiology and molecular genetics. In: Gattaz WF, Busatto G, editors. Advances in Schizophrenia Research. New York: Springer. pp 19-50.
84. Vawter MP, Barrett T, Cheadle C, Sokolov BP, Wood WH 3rd, Donovan DM, et al. 2001. Application of cDNA microarrays to examine gene expression differences in schizophrenia. Brain Res Bull 55:641-650.
85. Virgo L, Humphries C, Mortimer A, Barnes T, Hirsch S, de Belleroche J. 1995. Cholecystokinin messenger RNA defi cit in frontal and temporal cerebral cortex in schizophrenia. Biol Psychiatry 37:694-701.
86. Voineskos AN, de Luca V, Bulgin NL, van Adrichem Q, Shaikh S, Lang DJ, et al. 2008. A family-based association study of the myelin-associated glycoprotein and 2',3'-cyclic nucleotide 3′-phosphodiesterase genes with schizophrenia. Psychiatr Genet 18:143-146.
87. Wang S, Fusaro G, Padmanabhan J, Chellappan SP. 2002. Prohibitin co-localizes with Rb in the nucleus and recruits N-CoR and HDAC1 for transcriptional repression. Oncogene 21:8388-8396.
88. Webster MJ, O'Grady J, Kleinman JE, Weickert CS. 2005. Glial fi brillary acidic protein mRNA levels in the cingulate cortex of individuals with depression, bipolar disorder and schizophrenia. Neuroscience 133:453-461.
89. Willson VJ, Graham JG, McQueen IN, Thompson RJ. 1980. Immunoreactive aldolase C in cerebrospinal fluid of patients with neurological disorders. Ann Clin Biochem 17:110-113.
90. Wong AH, Likhodi O, Trakalo J, Yusuf M, Sinha A, Pato CN, et al. 2005. Genetic and post-mortem mRNA analysis of the 14-3-3 genes that encode phosphoserine/threonine-binding regulatory proteins in schizophrenia and bipolar disorder. Schizophr Res 78:137-146.
91. Yamashita T, Hige T, Takahashi T. 2005. Vesicle endocytosis requires dynamin-dependent GTP hydrolysis at a fast CNS synapse. Science 307:124-127.
92. Yao JK, Reddy RD, van Kammen DP. 2001. Oxidative damage and schizophrenia: an overview of the evidence and its therapeutic implications. CNS Drugs 15:287-310.
93. Yung AR, Killackey EJ, Nelson B, McGorry PD. 2010. The impact of early intervention in schizophrenia. In: Gattaz WF, Busatto G, editors. Advances in Schizophrenia Research. New York: Springer. in press.
94. Zheng X, Wu SL, Hincapie M, Hancock WS. 2009. Study of the human plasma proteome of rheumatoid arthritis. J Chromatogr A 1216:3538-3545.
95. Zlobec I, Baker K, Terracciano LM, Lugli A. 2008. RHAMM, p21 combined phenotype identifi es microsatellite instability-high colorectal cancers with a highly adverse prognosis. Clin Cancer Res 14:3798-3806.